Literature DB >> 26298265

Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.

Yoorim Seo1, Eun Gyo Jeong1, Eun Sook Kim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26298265     DOI： 10.1007/s12020-015-0722-7

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

1.  Classification and pharmacology of progestins.

Authors:  Adolf E Schindler; Carlo Campagnoli; René Druckmann; Johannes Huber; Jorge R Pasqualini; Karl W Schweppe; Jos H H Thijssen
Journal:  Maturitas       Date:  2008 Sep-Oct       Impact factor: 4.342

2.  Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.

Authors:  L Anttila; P Koskinen; H L Kaihola; R Erkkola; K Irjala; K Ruutiainen
Journal:  Fertil Steril       Date:  1992-10       Impact factor: 7.329

3.  Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.

Authors:  V Hug; S Kau; G N Hortobagyi; L Jones
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640
  3 in total
  1 in total

1.  Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate.

Authors:  Erina Yuasa-Shibasaki; Sumiyasu Ishii; Shunichi Matsumoto; Takuya Tomaru; Kazuhiko Horiguchi; Aya Osaki; Atsushi Ozawa; Nobuyuki Shibusawa; Tetsurou Satoh; Masanobu Yamada
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.